Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Circulating amino acids and risk of peripheral artery disease in the PREDIMED Trial

  • Razquin, Cristina
  • Fitó Colomer, Montserrat
  • Martínez-González, Miguel Ángel, 1957-
Effective prevention and risk prediction are important for peripheral artery disease (PAD) due to its poor prognosis and the huge disease burden it produces. Circulating amino acids (AA) and their metabolites may serve as biomarkers of PAD risk, but they have been scarcely investigated. The objective was to prospectively analyze the associations of baseline levels of plasma AA (and their pathways) with subsequent risk of PAD and the potential effect modification by a nutritional intervention with the Mediterranean diet (MedDiet). A matched case-control study was nested in the PREDIMED trial, in which participants were randomized to three arms: MedDiet with tree nut supplementation group, MedDiet with extra-virgin olive oil (EVOO) supplementation group or control group (low-fat diet). One hundred and sixty-seven PAD cases were matched with 250 controls. Plasma AA was measured with liquid chromatography/mass spectrometry at the Broad Institute. Baseline tryptophan, serine and threonine were inversely associated with PAD (ORfor 1 SD increase = 0.78 (0.61–0.99); 0.67 (0.51–0.86) and 0.75 (0.59–0.95), respectively) in a multivariable-adjusted conditional logistic regression model. The kynurenine/tryptophan ratio was directly associated with PAD (ORfor 1 SD increase = 1.50 (1.14–1.98)). The nutritional intervention with the MedDiet+nuts modified the association between threonine and PAD (p-value interaction = 0.018) compared with the control group. However, subjects allocated to the MedDiet+EVOO group were protected against PAD independently of baseline threonine. Plasma tryptophan, kynurenine/tryptophan ratio, serine and threonine might serve as early biomarkers of future PAD in subjects at a high risk of cardiovascular disease. The MedDiet supplemented with EVOO exerted a protective effect, regardless of baseline levels of threonine., This work was supported by the National Institutes of Health research grant R01HL118264 (1R01HL118264-01/2R01HL118264-05/2R01HL118264-09). The PREDIMED trial was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140 to Ramón Estruch during 2003–2005; RTIC RD 06/0045 to Miguel A. Martínez-González during 2006–2013 and through the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), and by grants from the Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462 and JR17/00022), the Ministerio de Ciencia e Innovación (AGL-2009–13906-C02, AGL2010–22319-C03 and SAF2016–80532-R), the Fundación Mapfre 2010 (no role in the design, implementation, analysis or interpretation of the data), the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVA-COMP2010–181, GVACOMP2011–151, CS2010-AP-111, PROMETEO 17/2017 and CS2011-AP-042), the Fundació La Marató-TV3 (grants 294/C/2015 and 538/U/2016 (no role in the design, implementation, analysis or interpretation of the data)) and the Regional Government of Navarra (P27/2011). Marta Guasch-Ferré was supported by the American Diabetes Association, grant #1-18-PMF-029. Jordi Salas-Salvadó was partially supported by ICREA under the ICREA Academia programme. Wittenbecher was supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant: KAW 2020.0239). Marta Guasch-Ferré was supported by NNF18CC0034900.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Glycolysis/gluconeogenesis- and tricarboxylic acid cycle-related metabolites, Mediterranean diet, and type 2 diabetes

  • Guasch-Ferré, Marta
  • Castañer, Olga
  • Fitó Colomer, Montserrat
  • Ruiz-Canela, Miguel
Background: Glycolysis/gluconeogenesis and tricarboxylic acid (TCA) cycle metabolites have been associated with type 2 diabetes (T2D). However, the associations of these metabolites with T2D incidence and the potential effect of dietary interventions remain unclear. Objectives: We aimed to evaluate the association of baseline and 1-y changes in glycolysis/gluconeogenesis and TCA cycle metabolites with insulin resistance and T2D incidence, and the potential modifying effect of Mediterranean diet (MedDiet) interventions. Methods: We included 251 incident T2D cases and 638 noncases in a nested case-cohort study within the PREDIMED Study during median follow-up of 3.8 y. Participants were allocated to MedDiet + extra-virgin olive oil, MedDiet + nuts, or control diet. Plasma metabolites were measured using a targeted approach by LC-tandem MS. We tested the associations of baseline and 1-y changes in glycolysis/gluconeogenesis and TCA cycle metabolites with subsequent T2D risk using weighted Cox regression models and adjusting for potential confounders. We designed a weighted score combining all these metabolites and applying the leave-one-out cross-validation approach. Results: Baseline circulating concentrations of hexose monophosphate, pyruvate, lactate, alanine, glycerol-3 phosphate, and isocitrate were significantly associated with higher T2D risk (17-44% higher risk for each 1-SD increment). The weighted score including all metabolites was associated with a 30% (95% CI: 1.12, 1.51) higher relative risk of T2D for each 1-SD increment. Baseline lactate and alanine were associated with baseline and 1-y changes of homeostasis model assessment of insulin resistance. One-year increases in most metabolites and in the weighted score were associated with higher relative risk of T2D after 1 y of follow-up. Lower risks were observed in the MedDiet groups than in the control group although no significant interactions were found after adjusting for multiple comparisons. Conclusions: We identified a panel of glycolysis/gluconeogenesis-related metabolites that was significantly associated with T2D risk in a Mediterranean population at high cardiovascular disease risk. A MedDiet could counteract the detrimental effects of these metabolites.This trial was registered at controlled-trials.com as ISRCTN35739639., Supported by NIH research grant NIDDK-R01DK 102896 (to FBH). The PREDIMED trial was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial (RTIC G03/140, to RE during 2003–2005; RTIC RD 06/0045, to MAM-G during 2006–2013; and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición); by Centro Nacional de Investigaciones Cardiovasculares grant CNIC 06/2007; Fondo de Investigación Sanitaria—Fondo Europeo de Desarrollo Regional grants PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462, and JR17/00022; Ministerio de Ciencia e Innovación grants AGL-2009–13906-C02, AGL2010–22319-C03, and SAF2016–80532-R; Fundación Mapfre 2010; Consejería de Salud de la Junta de Andalucía grant PI0105/2007; Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana grants ACOMP06109, GVA-COMP2010–181, GVACOMP2011–151, CS2010-AP-111, PROMETEO 17/2017, and CS2011-AP-042; Fundació La Marató-TV3 grants 294/C/2015 and 538/U/2016; and by Regional Government of Navarra grant P27/2011. MG-F was supported by American Diabetes Association grant #1-18-PMF-029. JLS was supported by Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) grant 1150416.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Depression and accelerated aging: the eveningness chronotype and low adherence to the mediterranean diet are associated with depressive symptoms in older subjects

  • Sorlí, José Vicente
  • Cámara, Edurne de la
  • Fernández-Carrión, Rebeca
  • Asensio, Eva M.
  • Portolés, Olga
  • Ortega-Azorín, Carolina
  • Pérez-Fidalgo, Alejandro
  • Villamil, Laura V.
  • Fitó Colomer, Montserrat
  • Barragán, Rocío
  • Coltell, Oscar
  • Corella, Dolores
Background and objectives: Depression often results in premature aging, which increases the risk of other chronic diseases, but very few studies have analyzed the association between epigenetic biomarkers of aging and depressive symptoms. Similarly, limited research has examined the joint effects of adherence to the Mediterranean diet (MedDiet) and chronotype on depressive symptoms, accounting for sex differences. Therefore, these are the objectives of our investigation in a Mediterranean population at high cardiovascular risk. Methods: We analyzed 465 older subjects (aged 55-75) with metabolic syndrome and assessed depressive symptoms by the Beck Depression Inventory (BDI-II). MedDiet adherence was measured with the 17-item MedDiet score, and chronotype with the Morningness-Eveningness Questionnaire (MEQ). Blood DNA methylation was analyzed, and epigenomic biomarkers of age acceleration were determined. We focused on the Dunedin Pace of Aging Computed from the Epigenome (DunedinPACE). We fitted multivariable models with interaction terms. Results: Prevalence of depression was statistically higher in women (p < 0.001). MedDiet adherence was strongly and inversely associated with depressive symptoms in the whole population (p < 0.01), while the MEQ score was inversely associated (p < 0.05). In the joint analysis, both MedDiet adherence and chronotype remained statistically associated with the BDI-II score (p < 0.05), showing additive effects. No interaction effects were observed. In women, a higher score in depressive symptoms was significantly associated with faster age acceleration (measured with the DunedinPACE biomarker). This association remained significant even after adjustment for MedDiet adherence and chronotype. Conclusions: In older subjects with metabolic syndrome, the eveningness chronotype was associated with greater depressive symptoms, but a higher adherence to the MedDiet could potentially counteract the chronotype risk with additive effects. Women showed stronger associations, and importantly, we reported for the first time in this population that depressive symptoms were associated with accelerated aging., This study was partially funded by the Spanish Ministry of Health (Instituto de Salud Carlos III) and the Ministerio de Economía y Competitividad-Fondo Europeo de Desarrollo Regional (FEDER) (grants CIBER 06/03, SAF2016-80532-R, PI13/00728, PI16/00366 and PI19/00781); the Generalitat Valenciana (grants PROMETEO2017/017, PROMETEO/2021/021; Programa Santiago Grisolía nº CIGRIS/2022/082); grant PID2019-108858RB-I00 funded by AEI 10.13039/501100011033 and by "ERDF A way of making Europe", and the Ministerio de Ciencia, Innovación y Universidades-AEI (grant PID2023-150110OB-I00).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Arginine catabolism metabolites and atrial fibrillation or heart failure risk: 2 case-control studies within the Prevención con Dieta Mediterránea (PREDIMED) trial

  • Goni, Leticia
  • Fitó Colomer, Montserrat
  • Ruiz-Canela, Miguel
Background Arginine-derived metabolites are involved in oxidative and inflammatory processes related to endothelial functions and cardiovascular risks. Objectives We prospectively examined the associations of arginine catabolism metabolites with the risks of atrial fibrillation (AF) or heart failure (HF), and evaluated the potential modifications of these associations through Mediterranean diet (MedDiet) interventions in a large, primary-prevention trial. Methods Two nested, matched, case-control studies were designed within the Prevención con Dieta Mediterránea (PREDIMED) trial. We selected 509 incident cases and 547 matched controls for the AF case-control study and 326 cases and 402 matched controls for the HF case-control study using incidence density sampling. Fasting blood samples were collected at baseline and arginine catabolism metabolites were measured using LC-tandem MS. Multivariable conditional logistic regression models were applied to test the associations between the metabolites and incident AF or HF. Interactions between metabolites and intervention groups (MedDiet groups compared with control group) were analyzed with the likelihood ratio test. Results Inverse association with incident AF was observed for arginine (OR per 1 SD, 0.83; 95% CI: 0.73–0.94), whereas a positive association was found for N1-acetylspermidine (OR for Q4 compared with Q1 1.58; 95% CI: 1.13–2.25). For HF, inverse associations were found for arginine (OR per 1 SD, 0.82; 95% CI: 0.69–0.97) and homoarginine (OR per 1 SD, 0.81; 95% CI: 0.68–0.96), and positive associations were found for the asymmetric dimethylarginine (ADMA) and symmetric dimethlyarginine (SDMA) ratio (OR per 1 SD, 1.19; 95% CI: 1.02–1.41), N1-acetylspermidine (OR per 1 SD, 1.34; 95% CI: 1.12–1.60), and diacetylspermine (OR per 1 SD, 1.20; 95% CI: 1.02–1.41). In the stratified analysis according to the dietary intervention, the lower HF risk associated with arginine was restricted to participants in the MedDiet groups (P-interaction = 0.044). Conclusions Our results suggest that arginine catabolism metabolites could be involved in AF and HF. Interventions with the MedDiet may contribute to strengthen the inverse association between arginine and the risk of HF. This trial was registered at controlled-trials.com as ISRCTN35739639., Supported by National Heart, Lung, and Blood Institute research grant R01HL118264 (to FBH). The PREDIMED (Prevención con Dieta Mediterránea) trial was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial: RTIC G03/140 (to RE) during 2003–2005 and RTIC RD 06/0045 (to MAM-G) during 2006–2013 and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (to MAM-G); Centro Nacional de Investigaciones Cardiovasculares grant CNIC 06/2007; Fondo de Investigación Sanitaria—Fondo Europeo de Desarrollo Regional grants PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462, and JR17/00022; Ministerio de Ciencia e Innovación grants AGL-2009-13906- C02, AGL2010-22319-C03, and SAF2016-80532-R; Fundación Mapfre 2010 (which had no role in the design, implementation, analysis, or interpretation of the data); Consejería de Salud de la Junta de Andalucía grant PI0105/2007; Public Health Division of the Department of Health of the Autonomous Government of Catalonia; Generalitat Valenciana grants ACOMP06109, GVA-COMP2010-181, GVACOMP2011-151, CS2010-AP111, PROMETEO 17/2017, and CS2011-AP-042; Fundació La MaratóTV3 (which had no role in the design, implementation, analysis, or interpretation of the data) grants 294/C/2015 and 538/U/2016; and Regional Government of Navarra grant P27/2011.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Sweet taste preference: Relationships with other tastes, liking for sugary foods and exploratory genome-wide association analysis in subjects with metabolic syndrome

  • Fernández-Carrión, Rebeca
  • Sorlí, José Vicente
  • Coltell, Oscar
  • Pascual, Eva C.
  • Ortega-Azorín, Carolina
  • Barragán, Rocío
  • Giménez-Alba, Ignacio M.
  • Alvarez-Sala, Andrea
  • Fitó Colomer, Montserrat
  • Ordovás, José M.
  • Corella, Dolores
Taste perception and its association with nutrition and related diseases (type 2 diabetes, obesity, metabolic syndrome, cardiovascular, etc.) are emerging fields of biomedicine. There is currently great interest in investigating the environmental and genetic factors that influence sweet taste and sugary food preferences for personalized nutrition. Our aims were: (1) to carry out an integrated analysis of the influence of sweet taste preference (both in isolation and in the context of other tastes) on the preference for sugary foods and its modulation by type 2 diabetes status; (2) as well as to explore new genetic factors associated with sweet taste preference. We studied 425 elderly white European subjects with metabolic syndrome and analyzed taste preference, taste perception, sugary-foods liking, biochemical and genetic markers. We found that type 2 diabetic subjects (38%) have a small, but statistically higher preference for sweet taste (p = 0.021) than non-diabetic subjects. No statistically significant differences (p > 0.05) in preferences for the other tastes (bitter, salty, sour or umami) were detected. For taste perception, type 2 diabetic subjects have a slightly lower perception of all tastes (p = 0.026 for the combined "total taste score"), bitter taste being statistically lower (p = 0.023). We also carried out a principal component analysis (PCA), to identify latent variables related to preferences for the five tastes. We identified two factors with eigenvalues >1. Factor 2 was the one with the highest correlation with sweet taste preference. Sweet taste preference was strongly associated with a liking for sugary foods. In the exploratory SNP-based genome-wide association study (GWAS), we identified some SNPs associated with sweet taste preference, both at the suggestive and at the genome-wide level, especially a lead SNP in the PTPRN2 (Protein Tyrosine Phosphatase Receptor Type N2) gene, whose minor allele was associated with a lower sweet taste preference. The PTPRN2 gene was also a top-ranked gene obtained in the gene-based exploratory GWAS analysis. In conclusion, sweet taste preference was strongly associated with sugary food liking in this population. Our exploratory GWAS identified an interesting candidate gene related with sweet taste preference, but more studies in other populations are required for personalized nutrition., This study was partially funded, by the Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana (grants PROMETEO 17/2017, PROMETEO/2021/021, APOSTD/2019/136 and APOSTD/2020/164); the Spanish Ministry of Health (Instituto de Salud Carlos III) and the Ministerio de Economía y Competitividad-Fondo Europeo de Desarrollo Regional (FEDER) (grants CIBER 06/03, PI06/1326, PI13/00728, PI16/00366, PI19/00781 and SAF2016–80532-R); grant PID2019-108858RB-I00 funded by AEI 10.13039/501100011033 and by “ERDF A way of making Europe”; the University Jaume I (grants UJI-B2018-69 and COGRUP/2016/06); the Ministerio de Universidad y Ciencia (FPU 18/01703); the Rei Jaume I Award for Medical Research 2018; and the US Department of Agriculture, Agriculture Research Service (grant 8050-51000-098-00D).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial

  • Martínez-González, Miguel Ángel, 1957-
  • Hernáez, Álvaro
  • Castañer, Olga
  • Salas Salvadó, Jordi
Background: Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet. Methods: PREDIMED (''PREvención con DIeta MEDiterránea'') was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8-< 10, 10- < 12, and 12-14 points. The outcome was new-onset type 2 diabetes. Results: Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70-0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25-0.83) for the highest (12-14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results. Conclusions: Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes. Trial registration ISRCTN35739639., Primary Funding Source Instituto de Salud Carlos III. The PREDIMED trial was supported by Instituto de Salud Carlos III (ISCIII), the official funding agency for biomedical research of the Spanish government, through grants provided to research networks specifically developed for the trial (RTIC G03/140, to Ramón Estruch during 2003–2005; RTIC RD 06/0045, to Miguel A. Martínez-González during 2006–2013 and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462, and JR17/00022), Ministerio de Ciencia e Innovación (AGL-2009–13906-C02, AGL2010- 22319-C03, AGL2011-23430, and SAF2016–80532-R), Fundación Mapfre 2010 (no role in the design, implementation, analysis or interpretation of the data), Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (PROMETEO 17/2017, and PROMETEO 21/2021), Fundació La Marató-TV3 (grants 294/C/2015 and 538/U/2016 (no role in the design, implementation, analysis or interpretation of the data)), Agencia Canaria de Investigación, Innovación y Sociedad de la Información-EU FEDER (PI 2007/050 and CS2011-AP-042), and Regional Government of Navarra (P27/2011). The metabolomic study was supported by research grant NIDDK-R01DK 102896 from the National Institutes of Health. Donations of olive oil, walnuts, almonds, and hazelnuts were made respectively by the Fundación Patrimonio Comunal Olivarero and Hojiblanca (Malaga, Spain), California Walnut Commission (Sacramento, California), Borges (Reus, Spain), and Morella Nuts (Reus, Spain). Prof. Jordi Salas-Salvadó is partially supported by ICREA, under the ICREA Academia programme.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Alteraciones mayores del electrocardiograma y riesgo cardiovascular en la población mediterránea de medio y alto riesgo

  • Pou Bordoy, Joan
  • Leiva, Alfonso
  • Albendín Ariza, Maria José
  • Elosua Llanos, Roberto
  • Rigo Carratalà, Fernando
  • Romaguera Bosch, Dora
  • Salas Salvadó, Jordi
  • Babio, Nancy
  • Martínez-González, Miguel Ángel, 1957-
  • Toledo, Estefania
  • Fitó Colomer, Montserrat
  • Arós, Fernando
  • Estruch, Ramón
  • Fiol, Miquel
Introducción: Las alteraciones mayores del electrocardiograma (AMECG) son frecuentes en personas de mediana y avanzada edad, y podrían ser un factor importante en la predicción de eventos cardiovasculares (ECV). Objetivo: Analizar la asociación entre AMECG (clasificación de Minnesota) y ECV independientemente de los factores de riesgo cardiovascular (FRCV) clásicos y valorar si mejoran la predicción de la función de riesgo FRESCO-Función de Riesgo Española de Acontecimientos Coronarios. Método: Se incluyeron 1.752 participantes del estudio PREDIMED entre 55 y 80 años con RCV medio o alto, con una media de seguimiento de 5,1 años. Durante el periodo de seguimiento se ha estimado la incidencia acumulada de ECV por sexo y presencia de AMECG, y analizado la asociación entre AMECG y ECV mediante regresión multivariante de Cox ajustadas por grupo de aleatorización y RCV (FRESCO). Para analizar la mejora en la predicción se calcularon los índices C de Harrel's, Nam d’Agostino, Net Reclassification Improvement e Integrated Discrimination Improvement. Resultados: Al inicio del estudio, un 25% de los participantes presentaron AMECG. Durante el seguimiento aparecieron 112 ECV (16 muertes cardiovasculares, 15 infartos agudo de miocardio, 38 anginas, 43 accidentes cerebrovasculares). Las AEMCG se asociaron a una mayor probabilidad de sufrir un ECV. En varones, las principales AMECG asociadas a la aparición de ECV fueron los criterios de hipertrofia de ventrículo izquierdo (HVE) con inversión de onda T (HR: 17,88; IC 95%: 5,51-58,03; p valor < 0,001) y el alargamiento de QT (HR: 2,41; IC 95%: 1,38-4,21; p valor = 0,002), y en mujeres la fibrilación auricular (HR: 5,7; IC 95%: 1,76-18,72; p valor = 0,006) y el descenso del ST (HR: 3,24; IC 95%: 1,36-7,71; p valor < 0,001). No se observó mejoría significativa en la capacidad predictiva de FRESCO al introducir las AMECG. Conclusiones: Las AMECG se asocian de manera independiente con los ECV, por lo que deben ser consideradas durante el curso del proceso clínico. Sin embargo, no ofrece una mejora adicional en la predicción del riesgo cardiovascular a la proporcionada por los factores de riesgo clásicos., Instituto de Salud Carlos III. El ensayo PREDIMED contó con el apoyo del Instituto de Salud Carlos III (ISCIII), la agencia oficial de financiamiento para la investigación biomédica del gobierno español, a través de subvenciones otorgadas a redes de investigación específicamente desarrolladas para el ensayo (RTIC G03/140, a Ramón Estruch durante 2003-2005; RTIC RD 06/0045, a Miguel A. Martínez-González durante 2006-2013 y a través del Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), y mediante subvenciones del Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462 y JR17/00022) financiadas por el Ministerio de Economía y Competitividad, Instituto Carlos III y también contó con el apoyo de fondos proporcionados por la Red de Atención Primaria y promoción de la Salud (RICAPPS) RD21/0016/0009, cofinanciado con fondos de Next Generation EU, que financian las actuaciones del Mecanismo de Recuperación y Resiliencia (MRR), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02, AGL2010-22319-C03, AGL2011-23430 y SAF2016-80532-R), Fundación Mapfre 2010 (sin participación en el diseño, implementación, análisis o interpretación de los datos), Consejería de Salud de la Junta de Andalucía (PI0105/2007), División de Salud Pública del Departamento de Salud de la Generalitat de Cataluña, Generalitat Valenciana (PROMETEO 17/2017 y PROMETEO 21/2021), Fundació La Marató-TV3 (subvenciones 294/C/2015 y 538/U/2016, sin participación en el diseño, implementación, análisis o interpretación de los datos)), Agencia Canaria de Investigación, Innovación y Sociedad de la Información-EU FEDER (PI 2007/050 y CS2011-AP-042), y Gobierno Regional de Navarra (P27/2011). El estudio metabolómico recibió el respaldo de la subvención de investigación NIDDK-R01DK 102896. Las donaciones de aceite de oliva, nueces, almendras y avellanas fueron realizadas, respectivamente, por la Fundación Patrimonio Comunal Olivarero y Hojiblanca (Málaga, España), California Walnut Commission (Sacramento, California), Borges (Reus, España) y Morella Nuts (Reus, España). El Prof. Jordi Salas-Salvadó cuenta con el apoyo parcial de ICREA, en el marco del programa ICREA Academia.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial

  • Martínez-González, Miguel Ángel, 1957-
  • Montero, Pedro
  • Ruiz-Canela, Miguel
  • Toledo, Estefanía
  • Estruch Riba, Ramon
  • Gómez-Gracia, Enrique
  • Li, Jun
  • Ros Rahola, Emilio
  • Arós, Fernando
  • Hernáez, Álvaro
  • Corella Piquer, Dolores
  • Fiol, Miquel
  • Lapetra, José
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Cofán Pujol, Montserrat
  • Sorlí, José V.
  • Babio, Nancy
  • Márquez-Sandoval, Yolanda F.
  • Castañer, Olga
  • Salas Salvadó, Jordi
Background Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet. Methods PREDIMED (‘‘PREvención con DIeta MEDiterránea’’) was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8–< 10, 10– < 12, and 12–14 points. The outcome was new-onset type 2 diabetes. Results Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70–0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25–0.83) for the highest (12–14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results. Conclusions Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial

  • Martínez-González, Miguel Ángel, 1957-
  • Hernáez, Álvaro
  • Castañer, Olga
  • Salas Salvadó, Jordi
Background: Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet. Methods: PREDIMED (''PREvención con DIeta MEDiterránea'') was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8-< 10, 10- < 12, and 12-14 points. The outcome was new-onset type 2 diabetes. Results: Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70-0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25-0.83) for the highest (12-14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results. Conclusions: Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes. Trial registration ISRCTN35739639., Primary Funding Source Instituto de Salud Carlos III. The PREDIMED trial was supported by Instituto de Salud Carlos III (ISCIII), the official funding agency for biomedical research of the Spanish government, through grants provided to research networks specifically developed for the trial (RTIC G03/140, to Ramón Estruch during 2003–2005; RTIC RD 06/0045, to Miguel A. Martínez-González during 2006–2013 and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462, and JR17/00022), Ministerio de Ciencia e Innovación (AGL-2009–13906-C02, AGL2010- 22319-C03, AGL2011-23430, and SAF2016–80532-R), Fundación Mapfre 2010 (no role in the design, implementation, analysis or interpretation of the data), Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (PROMETEO 17/2017, and PROMETEO 21/2021), Fundació La Marató-TV3 (grants 294/C/2015 and 538/U/2016 (no role in the design, implementation, analysis or interpretation of the data)), Agencia Canaria de Investigación, Innovación y Sociedad de la Información-EU FEDER (PI 2007/050 and CS2011-AP-042), and Regional Government of Navarra (P27/2011). The metabolomic study was supported by research grant NIDDK-R01DK 102896 from the National Institutes of Health. Donations of olive oil, walnuts, almonds, and hazelnuts were made respectively by the Fundación Patrimonio Comunal Olivarero and Hojiblanca (Malaga, Spain), California Walnut Commission (Sacramento, California), Borges (Reus, Spain), and Morella Nuts (Reus, Spain). Prof. Jordi Salas-Salvadó is partially supported by ICREA, under the ICREA Academia programme.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial

  • Martínez-González, Miguel Ángel, 1957-
  • Montero, Pedro
  • Ruiz-Canela, Miguel
  • Toledo, Estefanía
  • Estruch Riba, Ramon
  • Gómez-Gracia, Enrique
  • Li, Jun
  • Ros Rahola, Emilio
  • Arós, Fernando
  • Hernáez, Álvaro
  • Corella Piquer, Dolores
  • Fiol, Miquel
  • Lapetra, José
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Cofán Pujol, Montserrat
  • Sorlí, José V.
  • Babio, Nancy
  • Márquez-Sandoval, Yolanda F.
  • Castañer, Olga
  • Salas Salvadó, Jordi
Background Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet. Methods PREDIMED (‘‘PREvención con DIeta MEDiterránea’’) was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8–< 10, 10– < 12, and 12–14 points. The outcome was new-onset type 2 diabetes. Results Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70–0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25–0.83) for the highest (12–14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results. Conclusions Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Sweet taste preference: Relationships with other tastes, liking for sugary foods and exploratory genome-wide association analysis in subjects with metabolic syndrome

  • Fernández-Carrión, Rebeca
  • Sorlí, José Vicente
  • Coltell, Oscar
  • Pascual, Eva C.
  • Ortega-Azorín, Carolina
  • Barragán, Rocío
  • Giménez-Alba, Ignacio M.
  • Alvarez-Sala, Andrea
  • Fitó Colomer, Montserrat
  • Ordovás, José M.
  • Corella, Dolores
Taste perception and its association with nutrition and related diseases (type 2 diabetes, obesity, metabolic syndrome, cardiovascular, etc.) are emerging fields of biomedicine. There is currently great interest in investigating the environmental and genetic factors that influence sweet taste and sugary food preferences for personalized nutrition. Our aims were: (1) to carry out an integrated analysis of the influence of sweet taste preference (both in isolation and in the context of other tastes) on the preference for sugary foods and its modulation by type 2 diabetes status; (2) as well as to explore new genetic factors associated with sweet taste preference. We studied 425 elderly white European subjects with metabolic syndrome and analyzed taste preference, taste perception, sugary-foods liking, biochemical and genetic markers. We found that type 2 diabetic subjects (38%) have a small, but statistically higher preference for sweet taste (p = 0.021) than non-diabetic subjects. No statistically significant differences (p > 0.05) in preferences for the other tastes (bitter, salty, sour or umami) were detected. For taste perception, type 2 diabetic subjects have a slightly lower perception of all tastes (p = 0.026 for the combined "total taste score"), bitter taste being statistically lower (p = 0.023). We also carried out a principal component analysis (PCA), to identify latent variables related to preferences for the five tastes. We identified two factors with eigenvalues >1. Factor 2 was the one with the highest correlation with sweet taste preference. Sweet taste preference was strongly associated with a liking for sugary foods. In the exploratory SNP-based genome-wide association study (GWAS), we identified some SNPs associated with sweet taste preference, both at the suggestive and at the genome-wide level, especially a lead SNP in the PTPRN2 (Protein Tyrosine Phosphatase Receptor Type N2) gene, whose minor allele was associated with a lower sweet taste preference. The PTPRN2 gene was also a top-ranked gene obtained in the gene-based exploratory GWAS analysis. In conclusion, sweet taste preference was strongly associated with sugary food liking in this population. Our exploratory GWAS identified an interesting candidate gene related with sweet taste preference, but more studies in other populations are required for personalized nutrition., This study was partially funded, by the Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana (grants PROMETEO 17/2017, PROMETEO/2021/021, APOSTD/2019/136 and APOSTD/2020/164); the Spanish Ministry of Health (Instituto de Salud Carlos III) and the Ministerio de Economía y Competitividad-Fondo Europeo de Desarrollo Regional (FEDER) (grants CIBER 06/03, PI06/1326, PI13/00728, PI16/00366, PI19/00781 and SAF2016–80532-R); grant PID2019-108858RB-I00 funded by AEI 10.13039/501100011033 and by “ERDF A way of making Europe”; the University Jaume I (grants UJI-B2018-69 and COGRUP/2016/06); the Ministerio de Universidad y Ciencia (FPU 18/01703); the Rei Jaume I Award for Medical Research 2018; and the US Department of Agriculture, Agriculture Research Service (grant 8050-51000-098-00D).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Glycolysis/gluconeogenesis- and tricarboxylic acid cycle-related metabolites, Mediterranean diet, and type 2 diabetes

  • Guasch-Ferré, Marta
  • Castañer, Olga
  • Fitó Colomer, Montserrat
  • Ruiz-Canela, Miguel
Background: Glycolysis/gluconeogenesis and tricarboxylic acid (TCA) cycle metabolites have been associated with type 2 diabetes (T2D). However, the associations of these metabolites with T2D incidence and the potential effect of dietary interventions remain unclear. Objectives: We aimed to evaluate the association of baseline and 1-y changes in glycolysis/gluconeogenesis and TCA cycle metabolites with insulin resistance and T2D incidence, and the potential modifying effect of Mediterranean diet (MedDiet) interventions. Methods: We included 251 incident T2D cases and 638 noncases in a nested case-cohort study within the PREDIMED Study during median follow-up of 3.8 y. Participants were allocated to MedDiet + extra-virgin olive oil, MedDiet + nuts, or control diet. Plasma metabolites were measured using a targeted approach by LC-tandem MS. We tested the associations of baseline and 1-y changes in glycolysis/gluconeogenesis and TCA cycle metabolites with subsequent T2D risk using weighted Cox regression models and adjusting for potential confounders. We designed a weighted score combining all these metabolites and applying the leave-one-out cross-validation approach. Results: Baseline circulating concentrations of hexose monophosphate, pyruvate, lactate, alanine, glycerol-3 phosphate, and isocitrate were significantly associated with higher T2D risk (17-44% higher risk for each 1-SD increment). The weighted score including all metabolites was associated with a 30% (95% CI: 1.12, 1.51) higher relative risk of T2D for each 1-SD increment. Baseline lactate and alanine were associated with baseline and 1-y changes of homeostasis model assessment of insulin resistance. One-year increases in most metabolites and in the weighted score were associated with higher relative risk of T2D after 1 y of follow-up. Lower risks were observed in the MedDiet groups than in the control group although no significant interactions were found after adjusting for multiple comparisons. Conclusions: We identified a panel of glycolysis/gluconeogenesis-related metabolites that was significantly associated with T2D risk in a Mediterranean population at high cardiovascular disease risk. A MedDiet could counteract the detrimental effects of these metabolites.This trial was registered at controlled-trials.com as ISRCTN35739639., Supported by NIH research grant NIDDK-R01DK 102896 (to FBH). The PREDIMED trial was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial (RTIC G03/140, to RE during 2003–2005; RTIC RD 06/0045, to MAM-G during 2006–2013; and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición); by Centro Nacional de Investigaciones Cardiovasculares grant CNIC 06/2007; Fondo de Investigación Sanitaria—Fondo Europeo de Desarrollo Regional grants PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462, and JR17/00022; Ministerio de Ciencia e Innovación grants AGL-2009–13906-C02, AGL2010–22319-C03, and SAF2016–80532-R; Fundación Mapfre 2010; Consejería de Salud de la Junta de Andalucía grant PI0105/2007; Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana grants ACOMP06109, GVA-COMP2010–181, GVACOMP2011–151, CS2010-AP-111, PROMETEO 17/2017, and CS2011-AP-042; Fundació La Marató-TV3 grants 294/C/2015 and 538/U/2016; and by Regional Government of Navarra grant P27/2011. MG-F was supported by American Diabetes Association grant #1-18-PMF-029. JLS was supported by Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) grant 1150416.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Arginine catabolism metabolites and atrial fibrillation or heart failure risk: 2 case-control studies within the Prevención con Dieta Mediterránea (PREDIMED) trial

  • Goni, Leticia
  • Fitó Colomer, Montserrat
  • Ruiz-Canela, Miguel
Background Arginine-derived metabolites are involved in oxidative and inflammatory processes related to endothelial functions and cardiovascular risks. Objectives We prospectively examined the associations of arginine catabolism metabolites with the risks of atrial fibrillation (AF) or heart failure (HF), and evaluated the potential modifications of these associations through Mediterranean diet (MedDiet) interventions in a large, primary-prevention trial. Methods Two nested, matched, case-control studies were designed within the Prevención con Dieta Mediterránea (PREDIMED) trial. We selected 509 incident cases and 547 matched controls for the AF case-control study and 326 cases and 402 matched controls for the HF case-control study using incidence density sampling. Fasting blood samples were collected at baseline and arginine catabolism metabolites were measured using LC-tandem MS. Multivariable conditional logistic regression models were applied to test the associations between the metabolites and incident AF or HF. Interactions between metabolites and intervention groups (MedDiet groups compared with control group) were analyzed with the likelihood ratio test. Results Inverse association with incident AF was observed for arginine (OR per 1 SD, 0.83; 95% CI: 0.73–0.94), whereas a positive association was found for N1-acetylspermidine (OR for Q4 compared with Q1 1.58; 95% CI: 1.13–2.25). For HF, inverse associations were found for arginine (OR per 1 SD, 0.82; 95% CI: 0.69–0.97) and homoarginine (OR per 1 SD, 0.81; 95% CI: 0.68–0.96), and positive associations were found for the asymmetric dimethylarginine (ADMA) and symmetric dimethlyarginine (SDMA) ratio (OR per 1 SD, 1.19; 95% CI: 1.02–1.41), N1-acetylspermidine (OR per 1 SD, 1.34; 95% CI: 1.12–1.60), and diacetylspermine (OR per 1 SD, 1.20; 95% CI: 1.02–1.41). In the stratified analysis according to the dietary intervention, the lower HF risk associated with arginine was restricted to participants in the MedDiet groups (P-interaction = 0.044). Conclusions Our results suggest that arginine catabolism metabolites could be involved in AF and HF. Interventions with the MedDiet may contribute to strengthen the inverse association between arginine and the risk of HF. This trial was registered at controlled-trials.com as ISRCTN35739639., Supported by National Heart, Lung, and Blood Institute research grant R01HL118264 (to FBH). The PREDIMED (Prevención con Dieta Mediterránea) trial was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial: RTIC G03/140 (to RE) during 2003–2005 and RTIC RD 06/0045 (to MAM-G) during 2006–2013 and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (to MAM-G); Centro Nacional de Investigaciones Cardiovasculares grant CNIC 06/2007; Fondo de Investigación Sanitaria—Fondo Europeo de Desarrollo Regional grants PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462, and JR17/00022; Ministerio de Ciencia e Innovación grants AGL-2009-13906- C02, AGL2010-22319-C03, and SAF2016-80532-R; Fundación Mapfre 2010 (which had no role in the design, implementation, analysis, or interpretation of the data); Consejería de Salud de la Junta de Andalucía grant PI0105/2007; Public Health Division of the Department of Health of the Autonomous Government of Catalonia; Generalitat Valenciana grants ACOMP06109, GVA-COMP2010-181, GVACOMP2011-151, CS2010-AP111, PROMETEO 17/2017, and CS2011-AP-042; Fundació La MaratóTV3 (which had no role in the design, implementation, analysis, or interpretation of the data) grants 294/C/2015 and 538/U/2016; and Regional Government of Navarra grant P27/2011.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Circulating amino acids and risk of peripheral artery disease in the PREDIMED Trial

  • Razquin, Cristina
  • Fitó Colomer, Montserrat
  • Martínez-González, Miguel Ángel, 1957-
Effective prevention and risk prediction are important for peripheral artery disease (PAD) due to its poor prognosis and the huge disease burden it produces. Circulating amino acids (AA) and their metabolites may serve as biomarkers of PAD risk, but they have been scarcely investigated. The objective was to prospectively analyze the associations of baseline levels of plasma AA (and their pathways) with subsequent risk of PAD and the potential effect modification by a nutritional intervention with the Mediterranean diet (MedDiet). A matched case-control study was nested in the PREDIMED trial, in which participants were randomized to three arms: MedDiet with tree nut supplementation group, MedDiet with extra-virgin olive oil (EVOO) supplementation group or control group (low-fat diet). One hundred and sixty-seven PAD cases were matched with 250 controls. Plasma AA was measured with liquid chromatography/mass spectrometry at the Broad Institute. Baseline tryptophan, serine and threonine were inversely associated with PAD (ORfor 1 SD increase = 0.78 (0.61–0.99); 0.67 (0.51–0.86) and 0.75 (0.59–0.95), respectively) in a multivariable-adjusted conditional logistic regression model. The kynurenine/tryptophan ratio was directly associated with PAD (ORfor 1 SD increase = 1.50 (1.14–1.98)). The nutritional intervention with the MedDiet+nuts modified the association between threonine and PAD (p-value interaction = 0.018) compared with the control group. However, subjects allocated to the MedDiet+EVOO group were protected against PAD independently of baseline threonine. Plasma tryptophan, kynurenine/tryptophan ratio, serine and threonine might serve as early biomarkers of future PAD in subjects at a high risk of cardiovascular disease. The MedDiet supplemented with EVOO exerted a protective effect, regardless of baseline levels of threonine., This work was supported by the National Institutes of Health research grant R01HL118264 (1R01HL118264-01/2R01HL118264-05/2R01HL118264-09). The PREDIMED trial was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140 to Ramón Estruch during 2003–2005; RTIC RD 06/0045 to Miguel A. Martínez-González during 2006–2013 and through the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), and by grants from the Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462 and JR17/00022), the Ministerio de Ciencia e Innovación (AGL-2009–13906-C02, AGL2010–22319-C03 and SAF2016–80532-R), the Fundación Mapfre 2010 (no role in the design, implementation, analysis or interpretation of the data), the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVA-COMP2010–181, GVACOMP2011–151, CS2010-AP-111, PROMETEO 17/2017 and CS2011-AP-042), the Fundació La Marató-TV3 (grants 294/C/2015 and 538/U/2016 (no role in the design, implementation, analysis or interpretation of the data)) and the Regional Government of Navarra (P27/2011). Marta Guasch-Ferré was supported by the American Diabetes Association, grant #1-18-PMF-029. Jordi Salas-Salvadó was partially supported by ICREA under the ICREA Academia programme. Wittenbecher was supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant: KAW 2020.0239). Marta Guasch-Ferré was supported by NNF18CC0034900.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Alteraciones mayores del electrocardiograma y riesgo cardiovascular en la población mediterránea de medio y alto riesgo

  • Pou Bordoy, Joan
  • Leiva, Alfonso
  • Albendín Ariza, Maria José
  • Elosua Llanos, Roberto
  • Rigo Carratalà, Fernando
  • Romaguera Bosch, Dora
  • Salas Salvadó, Jordi
  • Babio, Nancy
  • Martínez-González, Miguel Ángel, 1957-
  • Toledo, Estefania
  • Fitó Colomer, Montserrat
  • Arós, Fernando
  • Estruch, Ramón
  • Fiol, Miquel
Introducción: Las alteraciones mayores del electrocardiograma (AMECG) son frecuentes en personas de mediana y avanzada edad, y podrían ser un factor importante en la predicción de eventos cardiovasculares (ECV). Objetivo: Analizar la asociación entre AMECG (clasificación de Minnesota) y ECV independientemente de los factores de riesgo cardiovascular (FRCV) clásicos y valorar si mejoran la predicción de la función de riesgo FRESCO-Función de Riesgo Española de Acontecimientos Coronarios. Método: Se incluyeron 1.752 participantes del estudio PREDIMED entre 55 y 80 años con RCV medio o alto, con una media de seguimiento de 5,1 años. Durante el periodo de seguimiento se ha estimado la incidencia acumulada de ECV por sexo y presencia de AMECG, y analizado la asociación entre AMECG y ECV mediante regresión multivariante de Cox ajustadas por grupo de aleatorización y RCV (FRESCO). Para analizar la mejora en la predicción se calcularon los índices C de Harrel's, Nam d’Agostino, Net Reclassification Improvement e Integrated Discrimination Improvement. Resultados: Al inicio del estudio, un 25% de los participantes presentaron AMECG. Durante el seguimiento aparecieron 112 ECV (16 muertes cardiovasculares, 15 infartos agudo de miocardio, 38 anginas, 43 accidentes cerebrovasculares). Las AEMCG se asociaron a una mayor probabilidad de sufrir un ECV. En varones, las principales AMECG asociadas a la aparición de ECV fueron los criterios de hipertrofia de ventrículo izquierdo (HVE) con inversión de onda T (HR: 17,88; IC 95%: 5,51-58,03; p valor < 0,001) y el alargamiento de QT (HR: 2,41; IC 95%: 1,38-4,21; p valor = 0,002), y en mujeres la fibrilación auricular (HR: 5,7; IC 95%: 1,76-18,72; p valor = 0,006) y el descenso del ST (HR: 3,24; IC 95%: 1,36-7,71; p valor < 0,001). No se observó mejoría significativa en la capacidad predictiva de FRESCO al introducir las AMECG. Conclusiones: Las AMECG se asocian de manera independiente con los ECV, por lo que deben ser consideradas durante el curso del proceso clínico. Sin embargo, no ofrece una mejora adicional en la predicción del riesgo cardiovascular a la proporcionada por los factores de riesgo clásicos., Instituto de Salud Carlos III. El ensayo PREDIMED contó con el apoyo del Instituto de Salud Carlos III (ISCIII), la agencia oficial de financiamiento para la investigación biomédica del gobierno español, a través de subvenciones otorgadas a redes de investigación específicamente desarrolladas para el ensayo (RTIC G03/140, a Ramón Estruch durante 2003-2005; RTIC RD 06/0045, a Miguel A. Martínez-González durante 2006-2013 y a través del Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), y mediante subvenciones del Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462 y JR17/00022) financiadas por el Ministerio de Economía y Competitividad, Instituto Carlos III y también contó con el apoyo de fondos proporcionados por la Red de Atención Primaria y promoción de la Salud (RICAPPS) RD21/0016/0009, cofinanciado con fondos de Next Generation EU, que financian las actuaciones del Mecanismo de Recuperación y Resiliencia (MRR), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02, AGL2010-22319-C03, AGL2011-23430 y SAF2016-80532-R), Fundación Mapfre 2010 (sin participación en el diseño, implementación, análisis o interpretación de los datos), Consejería de Salud de la Junta de Andalucía (PI0105/2007), División de Salud Pública del Departamento de Salud de la Generalitat de Cataluña, Generalitat Valenciana (PROMETEO 17/2017 y PROMETEO 21/2021), Fundació La Marató-TV3 (subvenciones 294/C/2015 y 538/U/2016, sin participación en el diseño, implementación, análisis o interpretación de los datos)), Agencia Canaria de Investigación, Innovación y Sociedad de la Información-EU FEDER (PI 2007/050 y CS2011-AP-042), y Gobierno Regional de Navarra (P27/2011). El estudio metabolómico recibió el respaldo de la subvención de investigación NIDDK-R01DK 102896. Las donaciones de aceite de oliva, nueces, almendras y avellanas fueron realizadas, respectivamente, por la Fundación Patrimonio Comunal Olivarero y Hojiblanca (Málaga, España), California Walnut Commission (Sacramento, California), Borges (Reus, España) y Morella Nuts (Reus, España). El Prof. Jordi Salas-Salvadó cuenta con el apoyo parcial de ICREA, en el marco del programa ICREA Academia.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Depression and accelerated aging: the eveningness chronotype and low adherence to the mediterranean diet are associated with depressive symptoms in older subjects

  • Sorlí, José Vicente
  • Cámara, Edurne de la
  • Fernández-Carrión, Rebeca
  • Asensio, Eva M.
  • Portolés, Olga
  • Ortega-Azorín, Carolina
  • Pérez-Fidalgo, Alejandro
  • Villamil, Laura V.
  • Fitó Colomer, Montserrat
  • Barragán, Rocío
  • Coltell, Oscar
  • Corella, Dolores
Background and objectives: Depression often results in premature aging, which increases the risk of other chronic diseases, but very few studies have analyzed the association between epigenetic biomarkers of aging and depressive symptoms. Similarly, limited research has examined the joint effects of adherence to the Mediterranean diet (MedDiet) and chronotype on depressive symptoms, accounting for sex differences. Therefore, these are the objectives of our investigation in a Mediterranean population at high cardiovascular risk. Methods: We analyzed 465 older subjects (aged 55-75) with metabolic syndrome and assessed depressive symptoms by the Beck Depression Inventory (BDI-II). MedDiet adherence was measured with the 17-item MedDiet score, and chronotype with the Morningness-Eveningness Questionnaire (MEQ). Blood DNA methylation was analyzed, and epigenomic biomarkers of age acceleration were determined. We focused on the Dunedin Pace of Aging Computed from the Epigenome (DunedinPACE). We fitted multivariable models with interaction terms. Results: Prevalence of depression was statistically higher in women (p < 0.001). MedDiet adherence was strongly and inversely associated with depressive symptoms in the whole population (p < 0.01), while the MEQ score was inversely associated (p < 0.05). In the joint analysis, both MedDiet adherence and chronotype remained statistically associated with the BDI-II score (p < 0.05), showing additive effects. No interaction effects were observed. In women, a higher score in depressive symptoms was significantly associated with faster age acceleration (measured with the DunedinPACE biomarker). This association remained significant even after adjustment for MedDiet adherence and chronotype. Conclusions: In older subjects with metabolic syndrome, the eveningness chronotype was associated with greater depressive symptoms, but a higher adherence to the MedDiet could potentially counteract the chronotype risk with additive effects. Women showed stronger associations, and importantly, we reported for the first time in this population that depressive symptoms were associated with accelerated aging., This study was partially funded by the Spanish Ministry of Health (Instituto de Salud Carlos III) and the Ministerio de Economía y Competitividad-Fondo Europeo de Desarrollo Regional (FEDER) (grants CIBER 06/03, SAF2016-80532-R, PI13/00728, PI16/00366 and PI19/00781); the Generalitat Valenciana (grants PROMETEO2017/017, PROMETEO/2021/021; Programa Santiago Grisolía nº CIGRIS/2022/082); grant PID2019-108858RB-I00 funded by AEI 10.13039/501100011033 and by "ERDF A way of making Europe", and the Ministerio de Ciencia, Innovación y Universidades-AEI (grant PID2023-150110OB-I00).